Dupilumab Effects Against Aeroallergen Challenge

Status Recruiting

Clinical Trial Summary

The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.

Clinical Trial Description

(i)Intervention #1: HDM exposures in the ACC This trial utilizes exposures to House dust mites (HDM) in the Aeroallergen Challenge Chamber (ACC) as a two-pronged tool for (i) precision phenotyping of HDM+PARC+AA+ persons to identify those with the adaptive and maladaptive phenotypes and (ii) assessment of symptoms intermittently throughout the clinical trial to monitor effects of dupilumab/placebo on symptom severity . (ii) Participants classifying to the adaptive and maladaptive phenotypes are then randomized to 18-weeks dupilumab vs. placebo, with ACC HDM visits during this phase. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05720325
Study type	Interventional
Source	The University of Texas Health Science Center at San Antonio
Contact	Sunil K Ahuja, MD
Phone	210-567-4823
Email	ahujas@uthscsa.edu
Status	Recruiting
Phase	Phase 2
Start date	March 29, 2023
Completion date	November 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04435990` - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites	Phase 3
Completed	`NCT03563521` - Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
Completed	`NCT02990117` - ICS Treatment Compliance of Asthma Patients
Completed	`NCT03468790` - Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.	Phase 3
Recruiting	`NCT04898283` - Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.	Phase 3
Recruiting	`NCT03455959` - Lung-Resident Memory Th2 Cells in Asthma	N/A
Not yet recruiting	`NCT05352126` - Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma.	N/A
Completed	`NCT01104012` - Validation of Proteomic Analyses for Allergic Asthma and Rhinitis	N/A
Not yet recruiting	`NCT06027073` - Biologics and Sublingual Immunotherapy	Phase 4
Completed	`NCT03112577` - Study of REGN3500 and Dupilumab in Patients With Asthma	Phase 1
Recruiting	`NCT04891237` - Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen	Phase 3
Terminated	`NCT02953106` - Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis	Phase 4
Completed	`NCT06063044` - Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Completed	`NCT03705325` - Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer	N/A
Recruiting	`NCT05478824` - IL13 Signaling in Allergic Asthma
Withdrawn	`NCT04035109` - Anakinra as a Rescue Treatment for Allergic Inflammation	Phase 1/Phase 2
Suspended	`NCT04109807` - Effects of Low Dose Ozone on Airway Inflammatory Responses in Adults With Asthma - Sedentary Nasal Ozone (Asthma SNOZ)	N/A
Recruiting	`NCT03983603` - Plant Stanol Esters and Preventing Asthma Symptoms	N/A
Not yet recruiting	`NCT05740748` - Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma	Phase 2